Product Description
Etoposide is a chemotherapy drug and is also known by its brand name Etopophos or Vepesid. You might have it as a treatment for a number of different types of cancer. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/etoposide)
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Korea, Lithuania, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russia, Serbia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 48
Highest Development Phases
Phase 3: Diffuse Large B-Cell Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Primary Central Nervous System Lymphoma|Small Cell Lung Cancer
Phase 2: Acute Myeloid Leukemia|Bladder Cancer|Breast Cancer|Carcinoma, Merkel Cell|Hodgkin Lymphoma|Large Cell Carcinoma|Lymphoma|Neuroendocrine Carcinoma|Pancreatic Cancer|Small Cell Carcinoma|T-Cell Peripheral Lymphoma|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Glo-BNHL | P3 |
Recruiting |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin |
2031-05-01 |
|
| IS24047 | P2 |
Recruiting |
Small Cell Lung Cancer |
2029-10-31 |
|
| CAAA601A42101 | P2 |
Recruiting |
Small Cell Lung Cancer |
2029-06-01 |
|
| CAAA601A42101 | P2 |
Not yet recruiting |
Small Cell Lung Cancer |
2029-06-01 |